Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
26 hedge funds and large institutions have $9.18M invested in Baudax Bio, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 13 closing their positions.
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
32% less funds holding
Funds holding: 38 → 26 (-12)
42% less call options, than puts
Call options by funds: $272K | Put options by funds: $467K
49% less capital invested
Capital invested by funds: $18.1M → $9.18M (-$8.87M)
85% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 13
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$118K |
| 2 |
Renaissance Technologies
New York
|
+$113K |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$99.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$90.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$31.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Corsair Capital Management
New York
|
-$1.42M |
| 2 |
Millennium Management
New York
|
-$769K |
| 3 |
NRC
North Run Capital
Boston,
Massachusetts
|
-$462K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$202K |
| 5 |
Jane Street
New York
|
-$164K |
BXRX Hedge Fund Activity: Q3 2020 in Review
26 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q3 2020, worth a combined $9.18M — down 49% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BXRX and 2 opened new positions — a net loss of 11 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Commonwealth Equity Services, adding an estimated $118K. The largest seller was Corsair Capital Management, cutting an estimated $1.42M.
- 26 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q3 2020, down from 38 in Q2 2020.
- Funds reported $9.18M of Baudax Bio, Inc. Common Stock stock for Q3 2020, down 49% quarter-over-quarter.
- 2 funds opened new Baudax Bio, Inc. Common Stock positions in Q3 2020 and 13 closed out, a net change of -11 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q3 2020 was Commonwealth Equity Services, an estimated $118K added.
- The largest Baudax Bio, Inc. Common Stock seller in Q3 2020 was Corsair Capital Management, an estimated $1.42M sold.
Based on aggregated 13F filings for Q3 2020.